Publications by authors named "Matthew D Falk"

Claim this Profile
P
Prokinetic actions of luminally acting 5-HT receptor agonists.
John R Konen, Melody M Haag, Daria Guseva, Molly Hurd, Alisha A Linton, Matthew D Falk

Neurogastroenterol Motil· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
Hengmiao Cheng, Suvi T M Orr, Simon Bailey, Alexei Brooun, Ping Chen, Matthew D Falk

J Med Chem· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Matthew D Falk

Proc Natl Acad Sci U S A· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
Ping Chen, Ya-Li Deng, Simon Bergqvist, Matthew D Falk, Wei Liu

Protein Sci· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzyme kinetics and distinct modulation of the protein kinase N family of kinases by lipid activators and small molecule inhibitors.
Matthew D Falk, Wei Liu, Ben Bolaños, Keziban Unsal-Kacmaz, Anke Klippel

Biosci Rep· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substrate selection influences molecular recognition in a screen for lymphoid tyrosine phosphatase inhibitors.
Rhushikesh A Kulkarni, Nadeem A Vellore, Matthew R Bliss, Stephanie M Stanford, Matthew D Falk

Chembiochem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Mark M Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Matthew D Falk

N Engl J Med· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45.
Stephanie M Stanford, Rekha G Panchal, Logan M Walker, Dennis J Wu, Matthew D Falk

Proc Natl Acad Sci U S A· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells.
Stephanie M Stanford, Divya Krishnamurthy, Matthew D Falk, Rossella Messina, Bikash Debnath

J Med Chem· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis